LUNSUMIO

all catalysts(0)

nothing on the calendar yet

News(6)

• Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
  Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.
  biospace · 8d ago
• Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
  Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
  biopharma_dive · 15d ago
• Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win
  Roche’s T cell engager Lunsumio has passed a Phase 3 trial in a slow-growing type of blood cancer, clearing the path for full approval and a broader label. Lunsumio is a bispecific antibody that ta…
  endpoints · 16d ago
• Roche bets up to $1B to advance next-gen bispecifics with Dualitas
  The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
  biospace · 16d ago
• Roche, Dualitas team up to find bispecific drugs for immune diseases
  Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
  biopharma_dive · 17d ago
• Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
  Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
  fiercebiotech · 17d ago